MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Intellia Therapeutics Inc

Затворен

СекторЗдравеопазване

7.33 11.06

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.53

Максимум

7.58

Ключови измерители

By Trading Economics

Приходи

6.8M

-129M

Продажби

3.8M

13M

EPS

-1.27

Марж на печалбата

-1,001.227

Служители

403

EBITDA

8.3M

-134M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+441.44% upside

Дивиденти

By Dow Jones

Следващи печалби

8.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-335M

838M

Предишно отваряне

-3.73

Предишно затваряне

7.33

Настроения в новините

By Acuity

26%

74%

73 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Intellia Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.09.2024 г., 17:01 ч. UTC

Топ новини

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12.09.2024 г., 11:00 ч. UTC

Топ новини

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Intellia Therapeutics Inc Прогноза

Ценова цел

By TipRanks

441.44% нагоре

12-месечна прогноза

Среден 36.06 USD  441.44%

Висок 74 USD

Нисък 9 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Intellia Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

20 ratings

15

Купи

4

Задържане

1

Продай

Техническа оценка

By Trading Central

N/A / 9.3Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

73 / 386 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.